Quick Answer
QuidelOrtho Corp reported Research And Development Expense of $186.20 million for the year ending 2025.
- QuidelOrtho Corp showed a decrease of -14.9% in Research And Development Expense from 2024 to 2025.
- This data is from QuidelOrtho Corp's annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $22.60 million | Q3 2021: $23.70 million | Q1 2022: $26.40 million | Q2 2022: $34.20 million | Q3 2022: $65.60 million | Q1 2023: $62.30 million | Q2 2023: $62.40 million | Q3 2023: $61.50 million | Q1 2024: $59.20 million | Q2 2024: $56.30 million | Q3 2024: $55.90 million | Q1 2025: $53.20 million | Q2 2025: $45.70 million | Q3 2025: $41.50 million.
- Over the full 6 years of available data (2020 to 2025), QuidelOrtho Corp's Research And Development Expense has grown by 120.9%.
- Historical annual values: Fiscal year 2025: $186.20 million | Fiscal year 2024: $218.70 million | Fiscal year 2023: $245.00 million | Fiscal year 2022: $187.90 million | Fiscal year 2021: $95.70 million | Fiscal year 2020: $84.30 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: